Building on the clinical promise of JDXZ granules for EGFR-TKI-induced skin toxicity demonstrated in this RCT, a follow-up RCT is warranted to rigorously assess the treatment’s efficacy and safety, with the goals of reducing skin toxicity and enhancing patient quality of life. The gene discussed is EGFR; the disease is dermatological toxicity.